MaltSci 麦伴科研

Appearance

Popular Reports / structural-biology

This report is written by MaltSci based on the latest literature and research findings

How does structural biology guide drug design? ​

Abstract ​

Structural biology has become a cornerstone in drug design, fundamentally transforming our understanding of molecular interactions and guiding the development of new therapeutics. By elucidating the three-dimensional structures of proteins, nucleic acids, and their complexes, structural biology provides invaluable insights that enable researchers to identify and characterize potential drug targets. The ability to visualize these biomolecules at an atomic level enhances our comprehension of their functional mechanisms and facilitates the rational design of drugs that can specifically interact with these targets. This review highlights the pivotal role of structural biology in drug design, focusing on various structural techniques, the principles of structure-based drug design (SBDD), and the integration of computational approaches in optimizing therapeutic development. Over the past few decades, advancements in structural biology techniques such as X-ray crystallography, NMR spectroscopy, and cryo-electron microscopy have revolutionized our capacity to visualize and understand the intricate details of biomolecular structures. These insights are critical for identifying molecular targets associated with diseases and addressing challenges such as drug resistance and genetic mutations. Current research emphasizes the transformative impact of structure-guided approaches on early drug discovery, where structural insights inform the entire drug development process—from target identification to lead optimization. The exploration of protein flexibility and dynamics is increasingly recognized as crucial for understanding drug-target interactions and optimizing lead compounds. This review encompasses an overview of structural biology techniques, their relevance in drug design, the principles and applications of SBDD, successful case studies, and the challenges faced in the field. It also considers future perspectives, particularly the emerging technologies in structural biology and the ongoing efforts to tackle drug resistance. Ultimately, this review underscores the synergistic relationship between structural biology and drug design, illustrating how advancements in understanding molecular structures drive innovations in therapeutic development and improve patient outcomes.

Outline ​

This report will discuss the following questions.

  • 1 Introduction
  • 2 The Role of Structural Biology in Drug Design
    • 2.1 Overview of Structural Biology Techniques
    • 2.2 Importance of Structural Insights in Target Identification
  • 3 Structure-Based Drug Design (SBDD)
    • 3.1 Principles of SBDD
    • 3.2 Case Studies of Successful SBDD Applications
  • 4 Fragment-Based Drug Discovery (FBDD)
    • 4.1 Introduction to FBDD
    • 4.2 Advantages and Challenges of FBDD
  • 5 Computational Approaches in Drug Design
    • 5.1 Molecular Modeling and Simulation
    • 5.2 In Silico Screening Techniques
  • 6 Future Perspectives and Challenges
    • 6.1 Emerging Technologies in Structural Biology
    • 6.2 Addressing Drug Resistance and Complex Targets
  • 7 Conclusion

1 Introduction ​

Structural biology has emerged as a cornerstone in the realm of drug design, fundamentally transforming our understanding of molecular interactions and guiding the development of new therapeutics. By elucidating the three-dimensional structures of proteins, nucleic acids, and their complexes, structural biology provides invaluable insights that enable researchers to identify and characterize potential drug targets. The ability to visualize these biomolecules at an atomic level not only enhances our comprehension of their functional mechanisms but also facilitates the rational design of drugs that can specifically interact with these targets. This review will delve into the pivotal role of structural biology in drug design, emphasizing the importance of various structural techniques, the principles of structure-based drug design (SBDD), and the integration of computational approaches in optimizing therapeutic development.

The significance of structural biology in drug design cannot be overstated. Over the past few decades, advancements in structural biology techniques such as X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, and cryo-electron microscopy have revolutionized our capacity to visualize and understand the intricate details of biomolecular structures [1][2]. These insights are critical for identifying molecular targets associated with diseases, including cancer and infectious diseases, and for addressing challenges such as drug resistance and the impact of genetic mutations [2]. As the pharmaceutical industry increasingly focuses on functional and structural genomics, the integration of structural biology into the drug discovery pipeline has become essential for developing novel therapeutics that are both effective and safe [1].

Current research highlights the transformative impact of structure-guided approaches on early drug discovery. Structural insights inform the entire drug development process, from target identification and validation to hit identification and lead optimization [3]. The ability to visualize the binding interactions between small molecules and their targets allows for the rational design of compounds with enhanced specificity and affinity [4]. Furthermore, the exploration of protein flexibility and dynamics is increasingly recognized as crucial for understanding drug-target interactions and optimizing lead compounds [5].

This review is organized into several key sections. We begin with an overview of structural biology techniques and their relevance in drug design, followed by a discussion on the importance of structural insights in target identification. The principles and applications of structure-based drug design (SBDD) will be examined, highlighting successful case studies that illustrate the effectiveness of this approach. We will also explore fragment-based drug discovery (FBDD), outlining its advantages and challenges in the context of drug development. Additionally, we will discuss computational approaches, including molecular modeling and in silico screening techniques, which are integral to predicting drug interactions and optimizing lead compounds [6].

In the latter sections, we will consider future perspectives and challenges in the field, particularly the emerging technologies in structural biology and the ongoing efforts to address drug resistance and the complexities of targeting multiple biomolecular interactions [7]. Ultimately, this review aims to underscore the synergistic relationship between structural biology and drug design, illustrating how advancements in understanding molecular structures are driving innovations in therapeutic development and improving patient outcomes. As we navigate the evolving landscape of drug discovery, the integration of structural insights will undoubtedly remain a vital component in the quest for effective and targeted therapies.

2 The Role of Structural Biology in Drug Design ​

2.1 Overview of Structural Biology Techniques ​

Structural biology plays a crucial role in guiding drug design by providing essential insights into the three-dimensional structures of biological macromolecules, particularly proteins that are often the targets for therapeutic interventions. The understanding of these structures enables the rational design of small molecules that can effectively interact with specific targets, thereby enhancing the potency and selectivity of potential drugs.

The process of structure-based drug design (SBDD) has been significantly advanced by the development of various structural biology techniques, including X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, and cryo-electron microscopy. These methods allow researchers to visualize the conformations of target proteins and their interactions with ligands at atomic resolution. For instance, the elucidation of the three-dimensional structure of a target protein can reveal binding sites, which can then be exploited to design small molecules that fit precisely into these sites, improving their binding affinity and specificity[8].

Furthermore, the integration of computational methods with structural biology enhances the drug design process. Molecular modeling and dynamics simulations help in understanding the flexibility and dynamics of proteins, which are critical for predicting how drugs will interact with their targets. Incorporating protein flexibility into docking studies allows for a more accurate assessment of ligand binding, which is essential given that biological macromolecules often exist in multiple conformations[5].

Structural biology also aids in addressing challenges such as drug resistance and the effects of mutations in genetic diseases. By understanding the structural basis of these issues, researchers can develop strategies to design new molecules that are less susceptible to resistance mechanisms, thus broadening the therapeutic potential of existing drugs[2].

Moreover, the advancements in structural biology techniques have facilitated the discovery of new modes of action for drugs and have enabled the screening of new types of ligands. This broadens the scope of drug discovery from merely optimizing existing compounds to exploring novel therapeutic avenues[9].

In summary, structural biology provides a foundational framework for drug design by elucidating the structures and dynamics of target proteins, informing the rational design of small molecules, and enhancing the understanding of complex biological interactions. This multifaceted approach ultimately accelerates the drug discovery process and improves the chances of developing effective therapies for various diseases.

2.2 Importance of Structural Insights in Target Identification ​

Structural biology plays a crucial role in guiding drug design by providing detailed insights into the three-dimensional structures of biological macromolecules, which are essential for understanding their functions and interactions. This understanding enables researchers to identify potential drug targets and design molecules that can effectively modulate their activity.

One of the fundamental contributions of structural biology to drug design is its ability to elucidate the mechanisms of action of small-molecule drugs. These compounds, typically low in molecular weight, target specific proteins involved in various molecular pathways. By visualizing the conformations and interactions of small molecules with their protein targets through techniques such as X-ray crystallography and nuclear magnetic resonance (NMR), researchers can design new chemical compounds that exhibit improved binding affinity and specificity (Kan 2002; Li and Kang 2020) [1][3].

Moreover, structural insights inform the drug discovery process at multiple stages, including target identification, validation, hit identification, and lead optimization. For instance, structural biology can reveal the binding modes of both orthosteric and allosteric inhibitors, thereby providing critical information on how to enhance the efficacy of drug candidates (Li and Kang 2020) [3]. The identification of druggable sites on target proteins, informed by structural data, is essential for rational drug design, allowing for the strategic modification of compounds to achieve desired therapeutic outcomes (Pandurangan et al. 2017) [2].

In addition, the advent of structural genomics has enabled the study of numerous targets in parallel, particularly focusing on membrane proteins, which represent a significant portion of drug targets. Despite the challenges associated with determining the structures of these proteins, ongoing advancements in technology and methodologies are enhancing our understanding of their roles in drug discovery (Lundstrom 2006) [10].

Furthermore, structure-based drug design (SBDD) integrates computational approaches to predict how drug candidates will interact with their targets. This process reduces the time and resources needed for drug development by allowing for the identification of potential candidates that fit the structural criteria established through prior research (van Montfort and Workman 2017) [4].

Overall, the integration of structural biology into drug design not only accelerates the discovery of novel therapeutics but also enhances the precision with which these drugs can be developed, ultimately leading to more effective treatments with fewer side effects. The continuous evolution of structural biology techniques promises to further expand its impact on the pharmaceutical industry, fostering innovation and improving patient outcomes.

3 Structure-Based Drug Design (SBDD) ​

3.1 Principles of SBDD ​

Structural biology plays a pivotal role in guiding drug design through the principles of Structure-Based Drug Design (SBDD). SBDD leverages the three-dimensional structures of biologically relevant targets, which are crucial for understanding how small molecular chemical ligands interact with these targets. This interaction is essential for the design of new compounds that exhibit improved binding affinity and specificity.

The foundation of SBDD lies in the advancements in structural biology, particularly the determination of protein structures using techniques such as X-ray crystallography and nuclear magnetic resonance. These techniques allow researchers to visualize the conformation and interactions of ligands bound to their target proteins, enabling the rational design of drugs. As highlighted by Kan (2002), the visualization of protein-ligand complexes is critical for developing new chemical compounds that can effectively modulate biological activity[1].

Moreover, SBDD is a multidisciplinary approach that integrates knowledge from various scientific fields, including computational biology, medicinal chemistry, and enzymology. This integration is vital for addressing complex biological targets and has been facilitated by advances in molecular biology and lab automation, which have increased the availability of genomic data and structural information[4].

Recent innovations in SBDD include the use of fragment-based approaches, which have led to the development of numerous clinical drug candidates and FDA-approved drugs, particularly in oncology[4]. Additionally, structure-based virtual screening (SBVS) has emerged as a significant tool within SBDD, enabling efficient lead discovery and optimization by understanding the molecular basis of diseases and utilizing the three-dimensional structures of biological targets[11].

The ongoing evolution of SBDD also emphasizes the importance of maintaining scientific rigor, as the quality of data obtained from structural biology significantly impacts the drug design process. The ability to generate high-resolution three-dimensional structures of drug targets is crucial, as these structures serve as the foundation for designing potent and selective inhibitors[12].

In conclusion, structural biology informs drug design through SBDD by providing essential insights into the molecular interactions between drugs and their targets. This knowledge not only accelerates the drug discovery process but also enhances the likelihood of developing effective therapeutic agents, addressing critical health challenges. The continuous advancements in structural biology and computational techniques are expected to further refine and improve the SBDD process, leading to more innovative drug development strategies[13][14].

3.2 Case Studies of Successful SBDD Applications ​

Structural biology plays a pivotal role in guiding drug design, particularly through the methodology known as Structure-Based Drug Design (SBDD). This approach utilizes the three-dimensional structures of biological macromolecules, such as proteins, to inform and enhance the drug discovery process. The integration of structural biology with computational methods allows for the rational design of new therapeutic agents that can interact more effectively with specific biological targets.

The success of SBDD is significantly attributed to advancements in structural biology, which have provided detailed insights into the conformation and interactions of proteins. For instance, the visualization of small molecule ligands bound to their protein targets in co-crystal structures enables researchers to design new chemical compounds with improved binding affinity and specificity. This organized, multidisciplinary endeavor has been facilitated by progress in molecular biology, lab automation, and computational science, leading to the identification of novel targets for drug discovery (Kan 2002).

Case studies exemplifying the successful application of SBDD highlight its effectiveness in various therapeutic areas. For example, advances in fragment-based drug design have resulted in over 30 clinical drug candidates and three FDA-approved drugs in oncology. These successes demonstrate the ability of SBDD to not only optimize existing compounds but also to innovate entirely new therapeutic strategies (van Montfort & Workman 2017). Moreover, structural biology has been instrumental in understanding disease mechanisms and guiding the design of drugs that are less susceptible to resistance, particularly in the context of genetic diseases and antibiotic resistance (Pandurangan et al. 2017).

The integration of computational modeling with experimental data has further refined SBDD. By incorporating knowledge of protein flexibility and dynamics into the design process, researchers can create drugs that are more effective in real biological systems (Barril & Fradera 2006). The ability to simulate molecular interactions at an atomic level enhances the understanding of both drug-target and off-target interactions, which is critical in the early phases of drug development (Skjevik et al. 2009).

Recent trends in drug design emphasize the need for a comprehensive approach that combines structural insights with machine learning and other data analytics methods. This approach aims to address challenges such as drug-likeness, target specificity, and off-target binding, ultimately leading to the development of more effective therapeutic agents (Velmurugan et al. 2020).

In conclusion, structural biology serves as a foundational element in the field of drug design, guiding the rational development of new therapeutics through SBDD. The methodology not only enhances the efficacy and specificity of drug candidates but also provides a framework for addressing complex challenges in drug discovery, as illustrated by numerous successful case studies in various therapeutic areas.

4 Fragment-Based Drug Discovery (FBDD) ​

4.1 Introduction to FBDD ​

Structural biology plays a pivotal role in guiding drug design, particularly through the framework of Fragment-Based Drug Discovery (FBDD). FBDD is a strategy that leverages structural insights to identify and optimize small chemical fragments that bind to biological targets, ultimately leading to the development of potent drug candidates.

The essence of FBDD lies in its reliance on structural biology techniques, such as X-ray crystallography and NMR spectroscopy, which provide detailed information about the binding modes of small fragments to their target proteins. These methods allow researchers to visualize how fragments interact with specific sites on proteins, facilitating the understanding of their mode of action at the molecular level. By analyzing the three-dimensional structures of protein-ligand complexes, scientists can discern critical interactions that contribute to binding affinity and specificity, which are essential for rational drug design[15].

One of the significant advantages of FBDD is its ability to explore a broader chemical space compared to traditional high-throughput screening (HTS). By focusing on low molecular weight fragments, researchers can identify hits that may not exhibit strong binding individually but can be optimized into more potent compounds through fragment growth or linking strategies[16]. The careful application of structural biology in FBDD enables the identification of binding hotspots on target proteins, which can then be exploited to enhance the efficacy of the drug candidates[17].

Furthermore, the integration of computational tools with structural biology has significantly improved the efficiency of FBDD. Computational methods can predict how fragments will interact with their targets, guiding the selection of fragments for further testing and optimization. This synergy between experimental and computational approaches facilitates a more systematic exploration of chemical space and accelerates the drug discovery process[18].

Overall, structural biology not only provides the foundational knowledge required for the successful application of FBDD but also enhances the ability to design high-quality drug candidates with improved physical and pharmacological properties. As the field of drug discovery continues to evolve, the importance of structural insights in guiding the design and optimization of new therapeutics remains paramount[19].

4.2 Advantages and Challenges of FBDD ​

Structural biology plays a pivotal role in guiding drug design, particularly within the framework of Fragment-Based Drug Discovery (FBDD). This methodology has gained traction as a robust alternative to traditional high-throughput screening (HTS) methods, facilitating the identification and optimization of small chemical compounds that can effectively bind to drug targets. The integration of structural biology into FBDD enables a deeper understanding of the interactions between small molecular fragments and their biological targets, which is essential for the rational design of effective therapeutics.

In FBDD, the identification of low molecular weight fragments that bind to specific targets is typically achieved through specialized detection methods. Structural biology techniques, such as X-ray crystallography and nuclear magnetic resonance (NMR) spectroscopy, are utilized to elucidate the binding modes of these fragments at an atomic level. This detailed structural information is critical as it allows medicinal chemists to optimize the fragments into drug-like candidates by enhancing their binding affinity and specificity. The use of structural data not only improves the likelihood of developing high-quality leads but also informs the optimization process, guiding modifications that enhance the physicochemical properties of the compounds [16][17][18].

The advantages of FBDD are manifold. One of the primary benefits is its ability to cover a broader chemical space compared to traditional drug discovery methods. FBDD can effectively target a wide array of biomolecules, including those considered challenging or undruggable, such as certain proteins and RNAs. The methodology allows for the generation of high-affinity ligands through the rational growth of fragment hits, which can be systematically optimized based on the structural insights gained [17][18]. Additionally, the incorporation of computational tools enhances the efficiency of FBDD, allowing for the rapid design and evaluation of potential drug candidates [20].

However, FBDD is not without its challenges. The process often involves lengthy timelines and can be resource-intensive, particularly in the early stages of fragment identification and optimization. The identification of suitable fragments that bind effectively to the target can be hindered by the inherent limitations of the chemical libraries used, as well as the complexity of the target's structure [21]. Furthermore, while FBDD has shown promise in various applications, the transition from fragment hits to lead compounds remains a significant hurdle, with many fragments failing to progress due to insufficient binding or unfavorable pharmacokinetic properties [22].

In conclusion, structural biology significantly enhances the drug design process through FBDD by providing essential insights into the molecular interactions between fragments and their targets. While FBDD presents distinct advantages in exploring new therapeutic avenues, it also faces challenges that necessitate ongoing refinement of methodologies and strategies to optimize the drug discovery pipeline. The continued evolution of structural biology and its integration with computational techniques will likely bolster the effectiveness of FBDD in future drug development endeavors [4][17][18].

5 Computational Approaches in Drug Design ​

5.1 Molecular Modeling and Simulation ​

Structural biology plays a pivotal role in guiding drug design through various computational approaches, particularly molecular modeling and simulation. This discipline provides essential insights into the three-dimensional structures of biological macromolecules, which are crucial for understanding biomolecular interactions at an atomic level. Such knowledge enables the rational design of drugs that can effectively target specific proteins or other biomolecules involved in diseases.

The integration of computational methodologies with structural biology enhances the drug development process by facilitating rational structure-based drug design. This approach utilizes molecular modeling to predict how small molecules, or ligands, interact with their biological targets. For instance, advancements in molecular dynamics simulations allow researchers to explore the flexibility and dynamics of these interactions, providing a more comprehensive understanding of ligand-binding energetics and the conformational changes that may occur upon binding [6].

Furthermore, the increasing throughput of structural biology techniques, such as X-ray crystallography and NMR spectroscopy, allows for the rapid determination of protein structures. These structures serve as templates for computational modeling, enabling the identification of potential binding sites and the design of new therapeutic compounds with improved binding affinities [9]. The application of in silico tools not only accelerates the discovery of new chemical modulators but also aids in the optimization of lead compounds by simulating their interactions within a biological context [23].

In addition, the rise of machine learning and artificial intelligence in structural biology has revolutionized drug design. These technologies enhance the predictive power of structural models, allowing for the rapid identification of promising drug candidates and the exploration of complex protein-ligand interactions [24]. By leveraging large datasets generated from molecular dynamics simulations and docking studies, researchers can gain deeper insights into the structure-function relationships of therapeutic targets [25].

The collaborative nature of structural biology and computational methods also fosters innovation in drug discovery. By creating immersive virtual environments for visualizing and manipulating molecular structures, researchers can democratize access to structural data, facilitating collaboration among scientists from diverse backgrounds [26]. This collaborative approach can lead to novel ideas and findings that may significantly impact the development of new therapeutics.

In summary, structural biology, through the application of molecular modeling and simulation techniques, provides critical insights that inform drug design. By elucidating the intricate details of biomolecular interactions, it enables the rational design of drugs that are more effective and tailored to specific targets, ultimately contributing to the advancement of therapeutic development.

5.2 In Silico Screening Techniques ​

Structural biology plays a pivotal role in guiding drug design, particularly through the utilization of computational approaches and in silico screening techniques. The integration of structural biology with computational methods has transformed drug discovery processes, allowing for more efficient and targeted design of therapeutic agents.

The essence of structure-based drug design (SBDD) lies in the three-dimensional understanding of biological macromolecules, primarily proteins. Knowledge of these structures, often obtained through techniques like X-ray crystallography and nuclear magnetic resonance (NMR), enables researchers to visualize how small molecular ligands interact with their targets. This visualization facilitates the design of new chemical compounds that exhibit improved binding affinity and specificity towards these targets (Kan 2002) [1].

Computational methods, including molecular docking, virtual high-throughput screening, and fragment-based drug design, are integral to SBDD. Molecular docking simulates the interaction between a ligand and its target protein, allowing researchers to predict the most favorable binding orientations and affinities. This method is particularly valuable for identifying potential lead compounds quickly and cost-effectively (Zoete et al. 2009) [27]. Furthermore, high-throughput screening techniques can evaluate large libraries of compounds in a short time, significantly accelerating the drug discovery process (Singla 2015) [28].

In silico techniques also aid in understanding the structure-function relationship of biomolecules. By utilizing computational tools, researchers can analyze the dynamics of receptor-ligand interactions, which are crucial for optimizing drug candidates. These approaches are less resource-intensive compared to traditional experimental methods, making them economically viable options in the drug development pipeline (Yadav et al. 2018) [23].

Additionally, the advancements in computational algorithms and the increasing availability of structural data have led to innovative methods in de novo drug design. These methods employ heuristics to explore vast chemical spaces, enabling the design of novel drug-like molecules that are both effective and synthetically accessible (Tang et al. 2024) [29]. The ability to combine structural insights with computational power has expanded the scope of drug discovery, addressing challenges such as drug resistance and the development of safer therapeutic options (Pandurangan et al. 2017) [2].

Overall, structural biology, complemented by computational approaches, significantly enhances the drug design process by providing critical insights into molecular interactions and guiding the development of targeted therapies. The synergy between these disciplines not only improves the efficiency of drug discovery but also fosters innovation in developing new therapeutic agents.

6 Future Perspectives and Challenges ​

6.1 Emerging Technologies in Structural Biology ​

Structural biology plays a pivotal role in guiding drug design by providing critical insights into the three-dimensional structures of biological macromolecules, particularly proteins, which are often the primary targets for drug development. The advent of advanced techniques such as X-ray crystallography, nuclear magnetic resonance (NMR), and cryo-electron microscopy has significantly enhanced our understanding of protein structures and their dynamics, thereby facilitating the rational design of therapeutic agents.

One of the primary contributions of structural biology to drug design is the ability to visualize the conformations and interactions of small molecule ligands bound to their protein targets. This visualization allows researchers to design new chemical compounds with improved binding affinity and specificity. The structural information aids in identifying potential binding sites, understanding the mechanisms of action, and optimizing lead compounds for better efficacy and reduced side effects [1].

Emerging technologies in structural biology, such as X-ray free-electron lasers and high-resolution cryo-electron microscopy, are revolutionizing drug discovery by enabling the rapid determination of complex structures. These advancements allow for the study of membrane proteins, which represent a significant portion of drug targets but have historically been challenging to characterize due to their complexity [4]. The integration of structural biology with computational methods, including machine learning and chemoinformatics, is also enhancing the drug design process. These methods enable the analysis of large datasets, improving the identification of drug-like properties and off-target interactions [30].

Despite these advancements, challenges remain. Structural biology can sometimes be misleading due to issues such as the interpretation of raw experimental data and the inherent flexibility of proteins, which can affect their functional states and interactions with drugs [31]. Furthermore, the increasing recognition of polypharmacology—where drugs interact with multiple targets—calls into question the traditional "one drug, one target" paradigm, necessitating a shift in how drugs are designed [32].

In summary, structural biology not only provides the foundational knowledge required for effective drug design but also faces ongoing challenges that must be addressed to fully leverage its potential in developing novel therapeutics. The future of drug design will likely hinge on the continued integration of structural biology with computational tools and the innovative application of emerging technologies to overcome existing limitations.

6.2 Addressing Drug Resistance and Complex Targets ​

Structural biology plays a pivotal role in guiding drug design by providing essential insights into the molecular interactions between drugs and their biological targets. The knowledge gained from structural biology facilitates a more informed approach to drug discovery, particularly in addressing challenges such as drug resistance and the complexities of targeting membrane proteins and other difficult targets.

For over four decades, structural biology has been utilized to comprehend disease mechanisms and inform drug discovery processes. Structure-guided methodologies have been demonstrated to contribute significantly to early drug discovery efforts, both computationally and experimentally. This field not only enhances our understanding of mutations in genetic diseases but also aids in tackling drug resistance in cancers and infectious diseases. By leveraging structural insights, researchers can repurpose existing drugs and design new molecules that are less likely to succumb to resistance mechanisms in the future (Pandurangan et al., 2017) [2].

The advancements in structural biology have broadened the scope of drug discovery from mere ligand optimization to addressing clinically relevant issues such as side effects and resistance. Breakthroughs in technology, including X-ray crystallography, NMR, and other biophysical methods, have enabled the rapid acquisition of structural information, allowing for a more comprehensive understanding of disease and therapeutic targets. For instance, the application of structure-based drug design (SBDD) has been particularly beneficial in developing drugs targeting integral membrane proteins, which have historically posed significant challenges (Hu et al., 2018) [9].

Moreover, structural biology provides crucial insights into the mechanisms of action for small molecules, which are essential for rational drug design. By elucidating the binding modes of both orthosteric and allosteric inhibitors, structural biology helps identify druggable sites and optimize lead compounds (Li & Kang, 2020) [3]. This is particularly relevant in the context of drug resistance, where understanding the conformational dynamics of targets can lead to the development of compounds that evade resistance pathways.

The rational design of drugs also involves computational methodologies that integrate structural data to predict drug-target interactions and optimize pharmacological properties. This approach is increasingly necessary in light of the growing complexity of drug targets and the need for drugs that exhibit polypharmacology—where a single drug can act on multiple targets, thus improving efficacy and reducing the likelihood of resistance (Hopkins et al., 2006) [32].

As drug discovery continues to evolve, structural biology will remain integral in addressing future challenges. The rise of multidrug-resistant pathogens highlights the need for innovative therapeutic strategies, such as antivirulence drugs that disarm pathogens without exerting selective pressure (Neville & Jia, 2019) [33]. The integration of structural biology with advanced computational methods and machine learning will further enhance the ability to design novel inhibitors tailored to specific disease mechanisms.

In summary, structural biology not only elucidates the intricate details of drug-target interactions but also empowers researchers to devise strategies to overcome drug resistance and tackle complex biological targets, paving the way for the next generation of therapeutics. The ongoing advancements in this field will be crucial for the future of drug design and discovery.

7 Conclusion ​

This review underscores the transformative impact of structural biology on drug design, emphasizing its critical role in understanding molecular interactions at an atomic level. The advancements in structural biology techniques, such as X-ray crystallography, NMR spectroscopy, and cryo-electron microscopy, have significantly enhanced our ability to visualize biomolecular structures, thereby informing the rational design of therapeutics. The principles of Structure-Based Drug Design (SBDD) and Fragment-Based Drug Discovery (FBDD) illustrate how structural insights can guide the identification and optimization of drug candidates, leading to more effective and targeted therapies. Moreover, the integration of computational approaches, including molecular modeling and in silico screening, has accelerated the drug discovery process by enabling the prediction of drug-target interactions and optimizing lead compounds. However, challenges such as drug resistance and the complexities of targeting multiple biomolecular interactions persist. Future research should focus on harnessing emerging technologies and refining methodologies to address these challenges, ensuring that structural biology continues to play a vital role in the development of innovative therapeutics that improve patient outcomes. As the field evolves, the synergistic relationship between structural biology and drug design will remain crucial in the quest for effective and safe treatments for various diseases.

References ​

  • [1] Chen-Chen Kan. Impact of recombinant DNA technology and protein engineering on structure-based drug design: case studies of HIV-1 and HCMV proteases.. Current topics in medicinal chemistry(IF=3.3). 2002. PMID:11944819. DOI: 10.2174/1568026023394218.
  • [2] Arun Prasad Pandurangan;David B Ascher;Sherine E Thomas;Tom L Blundell. Genomes, structural biology and drug discovery: combating the impacts of mutations in genetic disease and antibiotic resistance.. Biochemical Society transactions(IF=4.3). 2017. PMID:28408471. DOI: 10.1042/BST20160422.
  • [3] Qingxin Li;CongBao Kang. Mechanisms of Action for Small Molecules Revealed by Structural Biology in Drug Discovery.. International journal of molecular sciences(IF=4.9). 2020. PMID:32722222. DOI: 10.3390/ijms21155262.
  • [4] Rob L M van Montfort;Paul Workman. Structure-based drug design: aiming for a perfect fit.. Essays in biochemistry(IF=5.7). 2017. PMID:29118091. DOI: 10.1042/EBC20170052.
  • [5] Xavier Barril;Xavier Fradera. Incorporating protein flexibility into docking and structure-based drug design.. Expert opinion on drug discovery(IF=4.9). 2006. PMID:23495904. DOI: 10.1517/17460441.1.4.335.
  • [6] Age Aleksander Skjevik;Knut Teigen;Aurora Martinez. Overview of computational methods employed in early-stage drug discovery.. Future medicinal chemistry(IF=3.4). 2009. PMID:21426070. DOI: 10.4155/fmc.09.7.
  • [7] Marta Filizola;Jonathan A Javitch. Deciphering downstream receptor signaling.. Science (New York, N.Y.)(IF=45.8). 2023. PMID:38127769. DOI: 10.1126/science.adm8393.
  • [8] David G Brown;Elizabeth J Shotton. Diamond: shedding light on structure-based drug discovery.. Philosophical transactions. Series A, Mathematical, physical, and engineering sciences(IF=3.7). 2015. PMID:25624512. DOI: .
  • [9] Tiancen Hu;Elizabeth R Sprague;Michelle Fodor;Travis Stams;Kirk L Clark;Sandra W Cowan-Jacob. The impact of structural biology in medicine illustrated with four case studies.. Journal of molecular medicine (Berlin, Germany)(IF=4.2). 2018. PMID:28669027. DOI: 10.1007/s00109-017-1565-x.
  • [10] K Lundstrom. Structural genomics for membrane proteins.. Cellular and molecular life sciences : CMLS(IF=6.2). 2006. PMID:17013556. DOI: 10.1007/s00018-006-6252-y.
  • [11] Evanthia Lionta;George Spyrou;Demetrios K Vassilatis;Zoe Cournia. Structure-based virtual screening for drug discovery: principles, applications and recent advances.. Current topics in medicinal chemistry(IF=3.3). 2014. PMID:25262799. DOI: 10.2174/1568026614666140929124445.
  • [12] Jessica Lynn Grey;David H Thompson. Challenges and opportunities for new protein crystallization strategies in structure-based drug design.. Expert opinion on drug discovery(IF=4.9). 2010. PMID:21116481. DOI: 10.1517/17460441.2010.515583.
  • [13] Xin Wang;Ke Song;Li Li;Lijiang Chen. Structure-Based Drug Design Strategies and Challenges.. Current topics in medicinal chemistry(IF=3.3). 2018. PMID:30101712. DOI: 10.2174/1568026618666180813152921.
  • [14] Tao Wang;Mian-Bin Wu;Ri-Hao Zhang;Zheng-Jie Chen;Chen Hua;Jian-Ping Lin;Li-Rong Yang. Advances in Computational Structure-Based Drug Design and Application in Drug Discovery.. Current topics in medicinal chemistry(IF=3.3). 2016. PMID:26303430. DOI: 10.2174/1568026615666150825142002.
  • [15] Gerdien E de Kloe;David Bailey;Rob Leurs;Iwan J P de Esch. Transforming fragments into candidates: small becomes big in medicinal chemistry.. Drug discovery today(IF=7.5). 2009. PMID:19443265. DOI: 10.1016/j.drudis.2009.03.009.
  • [16] Christopher W Murray;Marcel L Verdonk;David C Rees. Experiences in fragment-based drug discovery.. Trends in pharmacological sciences(IF=19.9). 2012. PMID:22459076. DOI: 10.1016/j.tips.2012.02.006.
  • [17] Aanchal Kashyap;Pankaj Kumar Singh;Om Silakari. Counting on Fragment Based Drug Design Approach for Drug Discovery.. Current topics in medicinal chemistry(IF=3.3). 2018. PMID:30499406. DOI: 10.2174/1568026619666181130134250.
  • [18] Weijun Xu;Congbao Kang. Fragment-Based Drug Design: From Then until Now, and Toward the Future.. Journal of medicinal chemistry(IF=6.8). 2025. PMID:39992814. DOI: 10.1021/acs.jmedchem.5c00424.
  • [19] Leonardo G Ferreira;Adriano D Andricopulo. From Protein Structure to Small-Molecules: Recent Advances and Applications to Fragment-Based Drug Discovery.. Current topics in medicinal chemistry(IF=3.3). 2017. PMID:28240184. DOI: 10.2174/1568026617666170224113437.
  • [20] Valeria V Kleandrova;Alejandro Speck-Planche. The QSAR Paradigm in Fragment-Based Drug Discovery: From the Virtual Generation of Target Inhibitors to Multi-Scale Modeling.. Mini reviews in medicinal chemistry(IF=3.3). 2020. PMID:32013845. DOI: 10.2174/1389557520666200204123156.
  • [21] Jerica Wilson;Bahrad A Sokhansanj;Wei Chuen Chong;Rohan Chandraghatgi;Gail L Rosen;Hai-Feng Ji. Fragment databases from screened ligands for drug discovery (FDSL-DD).. Journal of molecular graphics & modelling(IF=3.0). 2024. PMID:38011826. DOI: 10.1016/j.jmgm.2023.108669.
  • [22] Elizabeth V Bedwell;William J McCarthy;Anthony G Coyne;Chris Abell. Development of potent inhibitors by fragment-linking strategies.. Chemical biology & drug design(IF=3.3). 2022. PMID:35854428. DOI: 10.1111/cbdd.14120.
  • [23] Tara Chand Yadav;Amit Kumar Srivastava;Arpita Dey;Naresh Kumar;Navdeep Raghuwanshi;Vikas Pruthi. Application of Computational Techniques to Unravel Structure-Function Relationship and their Role in Therapeutic Development.. Current topics in medicinal chemistry(IF=3.3). 2018. PMID:30465508. DOI: 10.2174/1568026619666181120142141.
  • [24] Haijian Li;Xiaolin Sun;Wenqiang Cui;Marc Xu;Junlin Dong;Babatunde Edukpe Ekundayo;Dongchun Ni;Zhili Rao;Liwei Guo;Henning Stahlberg;Shuguang Yuan;Horst Vogel. Computational drug development for membrane protein targets.. Nature biotechnology(IF=41.7). 2024. PMID:38361054. DOI: 10.1038/s41587-023-01987-2.
  • [25] Hanna Baltrukevich;Sabina Podlewska. From Data to Knowledge: Systematic Review of Tools for Automatic Analysis of Molecular Dynamics Output.. Frontiers in pharmacology(IF=4.8). 2022. PMID:35359865. DOI: 10.3389/fphar.2022.844293.
  • [26] Laura J Kingsley;Vincent Brunet;Gerald Lelais;Steve McCloskey;Kelly Milliken;Edgardo Leija;Stephen R Fuhs;Kai Wang;Edward Zhou;Glen Spraggon. Development of a virtual reality platform for effective communication of structural data in drug discovery.. Journal of molecular graphics & modelling(IF=3.0). 2019. PMID:30921557. DOI: 10.1016/j.jmgm.2019.03.010.
  • [27] Vincent Zoete;Aurélien Grosdidier;Olivier Michielin. Docking, virtual high throughput screening and in silico fragment-based drug design.. Journal of cellular and molecular medicine(IF=4.2). 2009. PMID:19183238. DOI: 10.1111/j.1582-4934.2008.00665.x.
  • [28] Rajeev K Singla. Editorial: in silico drug design and medicinal chemistry).. Current topics in medicinal chemistry(IF=3.3). 2015. PMID:25860175. DOI: 10.2174/156802661511150408110453.
  • [29] Yidan Tang;Rocco Moretti;Jens Meiler. Recent Advances in Automated Structure-Based De Novo Drug Design.. Journal of chemical information and modeling(IF=5.3). 2024. PMID:38485516. DOI: 10.1021/acs.jcim.4c00247.
  • [30] Devadasan Velmurugan;R Pachaiappan;Chandrasekaran Ramakrishnan. Recent Trends in Drug Design and Discovery.. Current topics in medicinal chemistry(IF=3.3). 2020. PMID:32568020. DOI: 10.2174/1568026620666200622150003.
  • [31] James S Fraser;Mark A Murcko. Structure is beauty, but not always truth.. Cell(IF=42.5). 2024. PMID:38306978. DOI: 10.1016/j.cell.2024.01.003.
  • [32] Andrew L Hopkins;Jonathan S Mason;John P Overington. Can we rationally design promiscuous drugs?. Current opinion in structural biology(IF=7.0). 2006. PMID:16442279. DOI: 10.1016/j.sbi.2006.01.013.
  • [33] Nolan Neville;Zongchao Jia. Approaches to the Structure-Based Design of Antivirulence Drugs: Therapeutics for the Post-Antibiotic Era.. Molecules (Basel, Switzerland)(IF=4.6). 2019. PMID:30678155. DOI: 10.3390/molecules24030378.

MaltSci Intelligent Research Services ​

Search for more papers on MaltSci.com ​

Structural Biology · Drug Design · Molecular Targets

© 2025 MaltSci